A citation-based method for searching scientific literature

Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel, Coert J Zuurbier. Diabetologia 2018
Times Cited: 197



Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann, Waheed Jamal, Karen Kimura, Janet Schnee, Cordula Zeller, Daniel Cotton, Edimar Bocchi, Michael Böhm, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure, Nadia Giannetti, Stefan Janssens, Jian Zhang, Jose R Gonzalez Juanatey, Sanjay Kaul, Hans-Peter Brunner-La Rocca, Bela Merkely, Stephen J Nicholls, Sergio Perrone, Ileana Pina, Piotr Ponikowski, Naveed Sattar, Michele Senni, Marie-France Seronde, Jindrich Spinar, Iain Squire, Stefano Taddei, Christoph Wanner, Faiez Zannad. N Engl J Med 2020
Times Cited: 677




List of shared articles



Times cited

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021
15

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Carlos G Santos-Gallego, Ariana P Vargas-Delgado, Juan Antonio Requena-Ibanez, Alvaro Garcia-Ropero, Donna Mancini, Sean Pinney, Frank Macaluso, Samantha Sartori, Merce Roque, Fernando Sabatel-Perez,[...]. J Am Coll Cardiol 2021
57

SGLT2-inhibitors; more than just glycosuria and diuresis.
Amir Fathi, Keeran Vickneson, Jagdeep S Singh. Heart Fail Rev 2021
6

Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis.
Alex Ali Sayour, Csilla Celeng, Attila Oláh, Mihály Ruppert, Béla Merkely, Tamás Radovits. Diabetologia 2021
4

SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms.
Maja Nikolic, Vladimir Zivkovic, Jovana Joksimovic Jovic, Jasmina Sretenovic, Goran Davidovic, Stefan Simovic, Danijela Djokovic, Nemanja Muric, Sergey Bolevich, Vladimir Jakovljevic. Heart Fail Rev 2021
6

Impact of Canagliflozin in Patients with Type 2 Diabetes after Hospitalization for Acute Heart Failure: A Cohort Study.
Ernesto Martín, José López-Aguilera, Rafael González-Manzanares, Manuel Anguita, Guillermo Gutiérrez, Aurora Luque, Nick Paredes, Jesús Oneto, Jorge Perea, Juan Carlos Castillo. J Clin Med 2021
0

Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy.
Amit K Rai, Brooke Lee, Ramesh Gomez, Deepu Rajendran, Mahmood Khan, Venkata Naga Srikanth Garikipati. Front Physiol 2021
1

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure.
Shruti S Joshi, Trisha Singh, David E Newby, Jagdeep Singh. Heart 2021
10

3



Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin.
Koenraad Philippaert, Subha Kalyaanamoorthy, Mohammad Fatehi, Wentong Long, Shubham Soni, Nikole J Byrne, Amy Barr, Jyoti Singh, Jordan Wong, Taylor Palechuk,[...]. Circulation 2021
10

Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.
Moritz J Hundertmark, Olorunsola F Agbaje, Ruth Coleman, Jyothis T George, Rolf Grempler, Rury R Holman, Hanan Lamlum, Jisoo Lee, Joanne E Milton, Heiko G Niessen,[...]. ESC Heart Fail 2021
2

Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.
Giuseppe Palmiero, Arturo Cesaro, Erica Vetrano, Pia Clara Pafundi, Raffaele Galiero, Alfredo Caturano, Elisabetta Moscarella, Felice Gragnano, Teresa Salvatore, Luca Rinaldi,[...]. Int J Mol Sci 2021
5

Implications of SGLT Inhibition on Redox Signalling in Atrial Fibrillation.
David Bode, Lukas Semmler, Christian U Oeing, Alessio Alogna, Gabriele G Schiattarella, Burkert M Pieske, Frank R Heinzel, Felix Hohendanner. Int J Mol Sci 2021
0

An evaluation of canagliflozin for the treatment of type 2 diabetes: an update.
Taichi Minami, Akiko Kameda, Yasuo Terauchi. Expert Opin Pharmacother 2021
0

Effects of Sodium-Glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice.
Dominique Croteau, Ivan Luptak, Jordan M Chambers, Ion Hobai, Marcello Panagia, David R Pimentel, Deborah A Siwik, Fuzhong Qin, Wilson S Colucci. J Am Heart Assoc 2021
3

SGLT2 Inhibition on Cardiac Mitochondrial Function: Searching for a Sweet Spot.
Konrad Teodor Sawicki, Issam Ben-Sahra, Elizabeth M McNally. J Am Heart Assoc 2021
1

Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species.
Xiaoling Li, Gregor Römer, Raphaela P Kerindongo, Jeroen Hermanides, Martin Albrecht, Markus W Hollmann, Coert J Zuurbier, Benedikt Preckel, Nina C Weber. Int J Mol Sci 2021
3

Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms.
Lei Xiao, Xin Nie, Yanyan Cheng, Nanping Wang. Cardiovasc Drugs Ther 2021
1

The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
Jiang Liu, Jiang Tian, Komal Sodhi, Joseph I Shapiro. J Membr Biol 2021
1

Diabetic proximal tubulopathy: Can we mimic the disease for in vitro screening of SGLT inhibitors?
João Faria, Karin G F Gerritsen, Tri Q Nguyen, Silvia M Mihaila, Rosalinde Masereeuw. Eur J Pharmacol 2021
0

Cardioprotection by SGLT2 Inhibitors-Does It All Come Down to Na+?
Maximilian Trum, Johannes Riechel, Stefan Wagner. Int J Mol Sci 2021
2

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence.
Manasvi Gupta, Shiavax Rao, Gaurav Manek, Gregg C Fonarow, Raktim K Ghosh. Ther Clin Risk Manag 2021
0

Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling.
William Durante, Ghazaleh Behnammanesh, Kelly J Peyton. Int J Mol Sci 2021
1


Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.
James P Curtain, Kieran F Docherty, Pardeep S Jhund, Mark C Petrie, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine,[...]. Eur Heart J 2021
6

SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?
Steffen Pabel, Nazha Hamdani, Mark Luedde, Samuel Sossalla. Curr Heart Fail Rep 2021
0

Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure.
Gloria M Gager, Dirk von Lewinski, Harald Sourij, Bernd Jilma, Ceren Eyileten, Krzysztof Filipiak, Martin Hülsmann, Jacek Kubica, Marek Postula, Jolanta M Siller-Matula. Biomed Pharmacother 2021
0

Effects of SGLT2 Inhibitors beyond Glycemic Control-Focus on Myocardial SGLT1.
Alex Ali Sayour, Mihály Ruppert, Attila Oláh, Kálmán Benke, Bálint András Barta, Eszter Zsáry, Béla Merkely, Tamás Radovits. Int J Mol Sci 2021
0


Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function.
Teresa Salvatore, Alfredo Caturano, Raffaele Galiero, Anna Di Martino, Gaetana Albanese, Erica Vetrano, Celestino Sardu, Raffaele Marfella, Luca Rinaldi, Ferdinando Carlo Sasso. Biomedicines 2021
0

Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions.
Andrea Passantino, Caterina Rizzo, Domenico Scrutinio, Alberto Palazzuoli. Heart Fail Rev 2021
0

SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence.
Luis D'Marco, Valery Morillo, José Luis Gorriz, María K Suarez, Manuel Nava, Ángel Ortega, Heliana Parra, Nelson Villasmil, Joselyn Rojas-Quintero, Valmore Bermúdez. J Diabetes Res 2021
0

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
Steffen Pabel, Nazha Hamdani, Jagdeep Singh, Samuel Sossalla. Front Physiol 2021
0